Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus | Zendy

Gemma A. Figtree | Zendy; Karin Rådholm | Zendy; Terrance D. Barrett | Zendy; Vlado Perkovic | Zendy; Kenneth W. Mahaffey | Zendy; Dick de Zeeuw | Zendy; Greg Fulcher | Zendy; David R. Matthews | Zendy; Wayne Shaw | Zendy; Bruce Neal | Zendy

Open Access

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

Author(s) -

Gemma A. Figtree,

Karin Rådholm,

Terrance D. Barrett,

Vlado Perkovic,

Kenneth W. Mahaffey,

Dick de Zeeuw,

Greg Fulcher,

David R. Matthews,

Wayne Shaw,

Bruce Neal

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.119.040057

Subject(s) - medicine , canagliflozin , ejection fraction , heart failure , cardiology , diabetes mellitus , type 2 diabetes , type 2 diabetes mellitus , endocrinology

Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF). Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabetes deemed to be at high risk based on established cardiovascular disease or multiple risk factors. However, it is unclear whether benefits are experienced across the broad spectrum of HF patients that includes those with preserved (HFpEF) as well as reduced ejection fraction (HFrEF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research